Dicerna Pharmaceuticals Inc (DRNA) Short Interest Update

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 335,400 shares, a drop of 52.7% from the January 12th total of 708,676 shares. Based on an average daily trading volume, of 502,823 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.9% of the shares of the company are short sold.

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at $9.31 on Friday. The company has a market cap of $493.69, a P/E ratio of -2.71 and a beta of 2.75. Dicerna Pharmaceuticals has a 1-year low of $2.48 and a 1-year high of $11.19.

In other news, Director Bain Capital Life Sciences Inv bought 285,000 shares of the company’s stock in a transaction on Monday, December 18th. The shares were purchased at an average price of $7.00 per share, with a total value of $1,995,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 29.41% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of DRNA. Northern Trust Corp raised its holdings in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,094 shares during the period. Birchview Capital LP raised its holdings in shares of Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 25,000 shares during the period. Emerald Advisers Inc. PA bought a new stake in shares of Dicerna Pharmaceuticals in the 4th quarter worth approximately $266,000. Deschutes Portfolio Strategy LLC bought a new stake in shares of Dicerna Pharmaceuticals in the 3rd quarter worth approximately $575,000. Finally, Vanguard Group Inc. raised its holdings in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares during the period. 22.76% of the stock is currently owned by institutional investors.

Several research firms have commented on DRNA. Evercore ISI began coverage on shares of Dicerna Pharmaceuticals in a research report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 target price on the stock. ValuEngine raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Chardan Capital reissued a “neutral” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, January 16th. Finally, BidaskClub cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $10.05.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/11/dicerna-pharmaceuticals-inc-drna-short-interest-update.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply